UW-Madison researcher working to shed light on the disability community’s experience during pandemic October 24, 2022

Isolation from family and loved ones, along with a forced split from routines and support systems, was part of life for everyone during the height of the COVID-19 pandemic — but those changes fell especially hard on the disability community. 

Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug

Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.